Nalaganje...

The Antitumor Drug LB-100 is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active Site Catalytic Metals in PPP5C

LB-100 is an experimental cancer-therapeutic with cytotoxic activity against cancer cells in culture and antitumor activity in animals. The first Phase I trial (NCT01837667) evaluating LB-100 recently concluded that safety and efficacy parameters are favorable for further clinical testing. Although...

Popoln opis

Shranjeno v:

Bibliografske podrobnosti
izdano v:	Mol Cancer Ther
Main Authors:	D’Arcy, Brandon M., Swingle, Mark R., Papke, Cinta M., Abney, Kevin A., Bouska, Erin S., Prakash, Aishwarya, Honkanen, Richard E.
Format:	Artigo
Jezik:	Inglês
Izdano:	2019
Teme:	Article
Online dostop:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6397705/ https://ncbi.nlm.nih.gov/pubmed/30679389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1143
Oznake:	Označite Brez oznak, prvi označite!

The Antitumor Drug LB-100 is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active Site Catalytic Metals in PPP5C

Podobne knjige/članki